دورية أكاديمية
أعرض في EDS

A transcriptome study of p53-pathway related prognostic gene signature set in bladder cancer.

التفاصيل البيبلوغرافية
العنوان: A transcriptome study of p53-pathway related prognostic gene signature set in bladder cancer.
المؤلفون: Khan SM; Clinical Biochemistry and Translational Medicine Laboratory, Department of Biochemistry and Molecular Biology, University of Dhaka, Dhaka, Bangladesh., Das T; Systems Cell-Signalling Laboratory, Department of Biochemistry and Molecular Biology, University of Dhaka, Dhaka, Bangladesh., Chakraborty S; Systems Cell-Signalling Laboratory, Department of Biochemistry and Molecular Biology, University of Dhaka, Dhaka, Bangladesh., Choudhury AMAR; Department. Uro-Oncology, National Institute of Cancer Research Hospital, Bangladesh., Karim HF; Department. Uro-Oncology, National Institute of Cancer Research Hospital, Bangladesh., Mostofa MA; Department. Uro-Oncology, National Institute of Cancer Research Hospital, Bangladesh., Ahmed HU; Clinical Biochemistry and Translational Medicine Laboratory, Department of Biochemistry and Molecular Biology, University of Dhaka, Dhaka, Bangladesh., Hossain MA; Clinical Biochemistry and Translational Medicine Laboratory, Department of Biochemistry and Molecular Biology, University of Dhaka, Dhaka, Bangladesh., Le Calvez-Kelm F; Genomic Epidemiology Branch, International Agency for Research on Cancer (IARC), 69372, Lyon, France., Hosen MI; Clinical Biochemistry and Translational Medicine Laboratory, Department of Biochemistry and Molecular Biology, University of Dhaka, Dhaka, Bangladesh., Shekhar HU; Clinical Biochemistry and Translational Medicine Laboratory, Department of Biochemistry and Molecular Biology, University of Dhaka, Dhaka, Bangladesh.
المصدر: Heliyon [Heliyon] 2023 Oct 14; Vol. 9 (10), pp. e21058. Date of Electronic Publication: 2023 Oct 14 (Print Publication: 2023).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Elsevier Ltd Country of Publication: England NLM ID: 101672560 Publication Model: eCollection Cited Medium: Print ISSN: 2405-8440 (Print) Linking ISSN: 24058440 NLM ISO Abbreviation: Heliyon Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: London : Elsevier Ltd, [2015]-
مستخلص: p53 pathway is important in tumorigenesis. However, no study has been performed to specifically investigate the role of p53 pathway genes in bladder cancer (BLCA). In this study, transcriptomics data of muscle invasive bladder cancer patients (n = 411) from The Cancer Genome Atlas (TCGA) were investigated. Using the hallmark p53 pathway gene set, the Non-Negative Matrix factorization (NMF) analysis identified two subtypes (C1 and C2). Clinical, survival, and immunological analysis were done to validate distinct characteristics of the subtypes. Pathway enrichment analysis showed the subtype C1 with poor prognosis having enrichment in genes of the immunity related pathways, where C2 subtype with better prognosis being enriched in genes of the steroid synthesis and drug metabolism pathways. A signature gene set consisting of MDGA2, GNLY, GGT2, UGT2B4, DLX1, and DSC1 was created followed by a risk model. Their expressions were analyzed in RNA extracted from the blood and matched tumor tissues of BLCA patients (n = 10). DSC1 had significant difference of expression (p = 0.005) between the blood and tumor tissues in our BLCA samples. Contrary to the usual normal bladder tissue to blood ratio, DLX1 expression was lower (p = 0.02734) in tumor tissues than in blood. Being the first research of p53 pathway related signature gene set in bladder cancer, this study potentially has a substantial impact on the development of biomarkers for BLCA.
Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(© 2023 Published by Elsevier Ltd.)
References: J Clin Pathol. 2012 Dec;65(12):1100-6. (PMID: 23002285)
Onco Targets Ther. 2017 Aug 14;10:4059-4063. (PMID: 28860814)
Eur Urol. 2017 Jan;71(1):96-108. (PMID: 27370177)
Urol Int. 2015;94(1):1-24. (PMID: 25501325)
Neoplasia. 2016 Oct;18(10):636-646. (PMID: 27690238)
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50. (PMID: 16199517)
J Cell Mol Med. 2020 Nov;24(22):13370-13382. (PMID: 33048468)
Nat Biotechnol. 2019 Jul;37(7):773-782. (PMID: 31061481)
Oman Med J. 2020 Mar 11;35(2):e103. (PMID: 32181005)
Lancet. 2016 Dec 3;388(10061):2796-2810. (PMID: 27345655)
World J Urol. 2018 Nov;36(11):1727-1740. (PMID: 29855698)
Front Oncol. 2019 Nov 20;9:1270. (PMID: 31824850)
World J Urol. 2007 Dec;25(6):563-71. (PMID: 17710407)
Front Mol Biosci. 2021 Jul 21;8:688298. (PMID: 34368227)
Recent Results Cancer Res. 2015;200:115-42. (PMID: 26376875)
Br J Cancer. 2012 Feb 14;106(4):756-62. (PMID: 22333708)
Genome Biol. 2011;12(4):R41. (PMID: 21527027)
Oncoimmunology. 2016 Feb 18;5(5):e1134412. (PMID: 27467953)
Nat Commun. 2015 Dec 04;6:8971. (PMID: 26634437)
Stat Med. 2013 Dec 30;32(30):5381-97. (PMID: 24027076)
Cancer Manag Res. 2019 Apr 12;11:2987-2995. (PMID: 31114346)
BMC Med Genomics. 2008 Apr 28;1:13. (PMID: 18442402)
Cell Cycle. 2006 Aug;5(15):1597-601. (PMID: 16880743)
Oncotarget. 2014 Sep 15;5(17):7917-35. (PMID: 25277204)
Nat Biotechnol. 2020 Jun;38(6):669-673. (PMID: 32444852)
Exp Cell Res. 2018 Feb 1;363(1):26-32. (PMID: 29317218)
Nat Rev Drug Discov. 2008 Dec;7(12):979-87. (PMID: 19043449)
Oncogene. 2006 Mar 13;25(11):1679-91. (PMID: 16550168)
Transl Oncol. 2020 Feb;13(2):193-200. (PMID: 31869744)
Cancer Discov. 2012 May;2(5):401-4. (PMID: 22588877)
Cell. 2017 Oct 19;171(3):540-556.e25. (PMID: 28988769)
Oncogene. 2017 Apr;36(15):2095-2104. (PMID: 27721403)
Sci Rep. 2020 Nov 12;10(1):19695. (PMID: 33184436)
Eur J Cancer. 2021 May;148:181-189. (PMID: 33743486)
Cancer Immunol Res. 2018 May;6(5):528-538. (PMID: 29588320)
J Cancer Res Clin Oncol. 2016 Dec;142(12):2461-2468. (PMID: 27601166)
Cancer Cell Int. 2018 May 02;18:68. (PMID: 29743818)
Cancers (Basel). 2021 Jun 15;13(12):. (PMID: 34203994)
Br J Cancer. 1995 Jan;71(1):201-5. (PMID: 7819040)
Methods. 2001 Dec;25(4):402-8. (PMID: 11846609)
Physiol Behav. 2017 Jul 1;176:139-148. (PMID: 28363838)
Int J Med Sci. 2020 Mar 5;17(6):762-772. (PMID: 32218698)
Nat Rev Dis Primers. 2017 Apr 13;3:17022. (PMID: 28406148)
Cancer Med. 2020 Apr;9(8):2774-2790. (PMID: 32096345)
Br J Cancer. 2006 Nov 20;95(10):1367-70. (PMID: 17088906)
Am J Pathol. 1999 Jul;155(1):105-13. (PMID: 10393843)
Front Mol Biosci. 2021 Jun 25;8:684050. (PMID: 34250018)
Nat Rev Clin Oncol. 2010 Jun;7(6):327-34. (PMID: 20421890)
Int J Clin Exp Pathol. 2015 Sep 01;8(9):11510-6. (PMID: 26617883)
CA Cancer J Clin. 2018 Nov;68(6):394-424. (PMID: 30207593)
Nat Commun. 2013;4:2612. (PMID: 24113773)
Nucleic Acids Res. 2016 Jan 4;44(D1):D733-45. (PMID: 26553804)
Nature. 2000 Nov 16;408(6810):307-10. (PMID: 11099028)
J Immunother Cancer. 2020 Jun;8(1):. (PMID: 32540859)
JAMA. 2020 Nov 17;324(19):1980-1991. (PMID: 33201207)
Int J Mol Sci. 2022 Apr 10;23(8):. (PMID: 35456991)
معلومات مُعتمدة: 001 International WHO_ World Health Organization
فهرسة مساهمة: Keywords: BLCA; Biomarker; DLX1; DSC1; Enrichment; NMF; Nomogram; Signature-set; TCGA; p53
تواريخ الأحداث: Date Created: 20231025 Latest Revision: 20240324
رمز التحديث: 20240324
مُعرف محوري في PubMed: PMC10590981
DOI: 10.1016/j.heliyon.2023.e21058
PMID: 37876438
قاعدة البيانات: MEDLINE
الوصف
تدمد:2405-8440
DOI:10.1016/j.heliyon.2023.e21058